CER Daily Newsfeed

Small but Important Differences Seen Between Rosuvastatin, Atorvastatin

(10/30, Lori Solomon, Medical Xpress) reports “...Shiyu Zhou, M.D., from Southern Medical University in Guangzhou, China, and colleagues compared the real-world effectiveness and safety of rosuvastatin and atorvastatin. The analysis included 285,680 eligible participants identified from the China Renal Data System (CRDS) and U.K. Biobank (UKB) databases...‘Rosuvastatin might be associated with cardiovascular and mortality benefits that need to be weighed against the risk for development of type 2 diabetes mellitus,’ the authors write.” Full

Video: Satish Rao, MD, PhD: Biofeedback Versus Dextranomer Hyaluronate for Fecal Incontinence

(10/30, Abigail Brooks, MA, HCPLive) “New research is providing novel insight into the comparative effectiveness of biofeedback and anal injection with dextranomer hyaluronate bulking agents for the treatment of fecal incontinence.” View Video

Penn Becomes National Coordinating Hub for Federal LHS E-STaR Network

(10/31, Hoag Levins, Penn LDI) reports “...The new LHS E-STaR programs will be training clinician scientists how to embed themselves as researchers within their own institutions to conduct internal analyses of the ongoing clinical and logistical operations. The new Penn national coordinating center will be called the SCALE-LHS Hub, which stands for ‘Synthesize, Coordinate, Amplify, Learn, and Evaluate the AHRQ/PCORI LHS network.’” Full

Drugmakers Urge Appeals Court to Revive Challenge to US Drug Price Negotiation Program

(10/30, Brendan Pierson, Reuters) reports “...Yaakov Roth of Jones Day, arguing for Bristol Myers, told a three-judge panel of the 3rd U.S. Circuit Court of Appeals on Wednesday that the law does not give the companies a choice to negotiate but is instead a ‘gun to the head,’ since a company that refuses to negotiate must pay exorbitant fines or drop out entirely from Medicare, which represents close to half of the prescription drug market.” Full